GET DAILY SIGNALSKaryopharm Therapeutics (KPTI) Shares Drop -83% Following Chapter 11 Bankruptcy Filing
Key Takeaways
- Karyopharm Therapeutics has not yet released its third-quarter 2026 results, which had been widely expected around late October to early November 2026.
- Consensus estimates pointed to quarterly revenue of roughly $33.5 million, with analysts projecting a net loss per share clustered around $0.95 to $1.16.
- On November 2, 2026, the company filed for Chapter 11 bankruptcy protection and announced a planned merger with Ayrmid Ltd., with the filing coming in lieu of the expected third-quarter earnings release.
- Karyopharm reported about $441.5 million in debt and secured commitments for up to $55 million in debtor-in-possession (DIP) financing, a loan that lets a bankrupt company keep operating during restructuring.
- In its most recent reported quarter (Q2 2026), Karyopharm posted a $2.32 per-share loss on $33.4 million in revenue, with U.S. XPOVIO (selinexor) net product revenue of $30.8 million.
- For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
- Discover Trending AI Robots for AI-driven market insights.
Why This Quarter Carries Extra Weight
This earnings period carries unusual weight because Karyopharm Therapeutics (KPTI)'s financial future, not just its operating results, is now in question. The company has been navigating mounting liquidity pressure while working to expand its lead therapy, XPOVIO (selinexor), an inhibitor of the exportin 1 (XPO1) protein, into myelofibrosis. After ending Q2 2026 with only $65.4 million in cash and a loan payment looming, management warned it might be unable to continue as a going concern. The decision to file for Chapter 11 protection on November 2, 2026, rather than report Q3 results, fundamentally reframes what investors are evaluating: near-term revenue trends, cash runway, and the terms of a court-supervised sale that could leave existing shareholders with little recovery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Wall Street’s Pre-Filing Expectations
Heading into the quarter, Wall Street's consensus anticipated roughly $33.5 million in third-quarter revenue, down from $44.04 million a year earlier. Analysts' loss-per-share forecasts ranged from about $0.78 to $1.16, reflecting continued operating losses. These estimates built on a mixed recent track record: Karyopharm beat revenue and earnings expectations in Q1 2026, then missed badly on earnings in Q2 2026, posting a $2.32 per-share loss versus a $1.31 consensus. Full-year 2026 guidance, reaffirmed in August, called for $130 million to $150 million in total revenue and combined R&D (research and development) plus SG&A (selling, general and administrative) spending of $230 million to $245 million. The November 2 bankruptcy filing means those figures may now take a backseat to restructuring terms.
Market Reaction and Shifting Sentiment
Sentiment has deteriorated sharply. On November 2, 2026, shares plunged roughly 83% to around $0.11 following the Chapter 11 filing, leaving the company with a market capitalization of only about $2.5 million. The reaction reflects a shift in how the stock is valued: rather than trading on Xpovio sales or pipeline potential, Karyopharm is now being evaluated on the likely recovery available to equity holders under a restructuring. Analysts at Rodman & Renshaw downgraded the stock and withdrew their price target, noting that secured lenders and noteholders are positioned to recover first, so any value left for common shareholders "could be minimal." With the planned Ayrmid merger expected to close in the first quarter of 2027, near-term trading is likely to remain driven by restructuring headlines rather than fundamentals.
Forward Outlook and Developments to Watch
Investors should watch several developments in the months ahead. The first is the bankruptcy court's approval of the up-to-$55 million DIP financing, which would let Karyopharm fund day-to-day operations during the restructuring. A court-supervised sale process is central to the plan, with Ayrmid Ltd. serving as the lead bidder, though competing bids may still emerge.
A second key item is the status of Karyopharm's myelofibrosis program. The company had submitted a supplemental new drug application to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for selinexor in combination with Incyte's Jakafi, with a potential decision expected in early 2027. How that regulatory review proceeds could influence the value assigned to the business in any sale.
Finally, monitor whether Karyopharm eventually reports its third-quarter financials. The absence of a traditional Q3 release means investors lack an updated view of Xpovio's U.S. sales trajectory and the company's cash position heading into restructuring. Until more details emerge, the central questions are the auction's outcome, the treatment of existing shareholders, and whether any competing bidder improves on Ayrmid's proposal. One thing that stands out is how quickly the focus has shifted from clinical milestones to legal proceedings.
AI Tools in My Biotech Research Process
When analyzing event-driven names like this, I find Tickeron's AI Screener helpful for quickly filtering biotech stocks by technical patterns, fundamentals, and volatility signals. It lets me compare performance across the sector without manually combing through dozens of filings, which keeps my process efficient during periods of high uncertainty like a restructuring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KPTI's Stochastic Oscillator is staying in overbought zone for 4 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KPTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KPTI broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KPTI entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KPTI's RSI Indicator exited the oversold zone, 23 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on KPTI as a result. In 84 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for KPTI just turned positive on October 19, 2026. Looking at past instances where KPTI's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.
Following a +83.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where KPTI advanced for three days, in 222 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.008) is normal, around the industry mean (3.162). P/E Ratio (-0.008) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.226) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. KPTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KPTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation
Industry Biotechnology
Advertisement